BTIG analyst Thomas Shrader raised the firm’s price target on BridgeBio to $42 from $32 and keeps a Buy rating on the shares. The price target increase reflects the very positive readout from Part B of ATTRibute-CM, with BTIG seeing the probability of success at 90% as the treatment effect was clear and statistically positive based solely on the historical composite of ACM + CV hospitalization, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BBIO:
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio downgraded to Hold on full valuation at Jefferies
- BridgeBio downgraded to Hold from Buy at Jefferies
- BridgeBio (NASDAQ:BBIO) Skyrockets on Promising Data in Heart Disease
- BridgeBio reports results from Phase 3 study of ATTR-CM